Noveltreat 2.4 mg Pre-filled Pen is a higher-strength once-weekly injectable medication. It is designed for chronic weight management in adults with Obesity or those who are overweight with at least one weight-related condition.
This medication contains an FDA-approved active ingredient, Semaglutide base (2.4 mg/0.75 ml), a Glucagon-like Peptide-1 (GLP-1) receptor agonist that replicates the action of natural incretin hormones. Sun Pharmaceuticals manufactures Noveltreat 2.4 mg in GMP-compliant facilities.
Semaglutide functions through multiple mechanisms. It delays gastric emptying to prolong satiety, acts on brain receptors to reduce hunger signals, and enhances insulin secretion while suppressing glucagon release. These combined effects contribute to reduced food intake, improved glycemic control, and sustainable weight reduction.
The Noveltreat injection is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm on the same day each week. Some of its common side effects are nausea, vomiting, diarrhea, constipation, and stomach pain. They typically subside as treatment continues.
Before initiating Noveltreat, disclose any history of Pancreatitis, thyroid tumors, gallbladder disease, kidney problems, or Diabetic Retinopathy (eye disease caused by Diabetes) to the healthcare provider. Store unopened Noveltreat 2.4 mg Pre-filled Pens refrigerated at 2°C to 8°C.
Once in use, the pen can remain at room temperature below 30°C or stay refrigerated for up to 6 weeks. Always keep the cap on between uses to shield from light, and properly dispose of used pens in an appropriate sharps container.
Noveltreat 2.4 mg Pre-filled Pen provides benefits for individuals seeking effective chronic weight management and improved metabolic health. Some of them include:
Noveltreat 2.4 mg Pre-filled Pen is a prescription medication requiring medical supervision. Follow these administration instructions carefully:
Noveltreat Pre-filled Pen is currently available in a single strength at Cheap Medicine Shop. However, the following effective alternatives are available:
| Wegovy 0.5 mg | $270.58/injection |
| Wegovy 0.25 mg | $270.58/injection |
| Wegovy 1 mg | $270.58/injection |
Like all medications, Noveltreat 2.4 mg Pre-filled Pen can cause mild side effects that usually improve as your body adapts to treatment. Contact a doctor if symptoms persist or become severe:
Liver Disease
Patients with liver disease should use Noveltreat 2.4 mg with appropriate medical supervision. It is vital to disclose pre-existing liver conditions to the healthcare provider to ensure safety.
Kidney Impairment
Exercise caution when using Noveltreat in patients with kidney impairment, especially those with severe dysfunction. While the medication itself doesn't require dose adjustment for mild to moderate kidney disease, gastrointestinal side effects can cause dehydration and potentially worsen kidney problems. Never use the medicine without medical consultation.
Pregnant and Breastfeeding women
Noveltreat 2.4 mg is contraindicated during pregnancy due to potential fetal risks. Stop treatment at least 2 months before planned conception. The transfer of Semaglutide into breast milk remains unknown, so nursing mothers should consult their healthcare provider to evaluate risks versus benefits before initiating or continuing treatment.
Avoid
Avoid Noveltreat in the case of personal or family history of cancers such as Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2), as the medication carries a thyroid tumor risk warning. Do not use it if allergic to Semaglutide. Patients with active or recent Pancreatitis and Type 1 Diabetes should avoid this medication.
Yes, Noveltreat 2.4 mg can be combined with various Diabetes medications, including Metformin and DPP-4 inhibitors. If you're taking insulin or sulfonylureas, your doctor will likely reduce your doses to minimize the chances of low blood sugar. However, it is vital to consult a doctor before combining any medicines.
Individuals with a history of MEN2, Medullary Thyroid Cancer, or severe allergic reactions to Semaglutide should not use Noveltreat 2.4 mg. This medication is inappropriate for Type 1 Diabetes or women who are pregnant or breastfeeding.
If your scheduled injection is missed and you remember within 5 days, administer it promptly and continue your regular weekly routine. If more than 5 days have passed since your missed dose, skip it and resume your normal injection day. Avoid taking two doses close together.
Yes, Semaglutide present in Noveltreat 2.4 mgf carries a warning regarding thyroid C-cell tumors. These effects were observed in animal studies, though human data are insufficient. So, if you experience a neck lump, hoarseness, difficulty swallowing, or persistent throat discomfort, report it to your healthcare provider immediately for evaluation.
Yes, Noveltreat 2.4 mg contains Semaglutide, which can cause serious risks like gallbladder disease, kidney problems, or severe gastrointestinal symptoms. Persistent abdominal pain, vomiting, or dehydration should not be ignored. In rare cases, it can also worsen diabetic eye conditions, especially in those with pre-existing Retinopathy (damaged retina).
Use Noveltreat cautiously if you have a history of Pancreatitis, kidney issues, or gastrointestinal disorders. Stay well hydrated and monitor for vision changes or severe stomach pain. Avoid abrupt dose escalation and follow your doctor’s dosing schedule carefully. Inform your healthcare provider about all ongoing medications and health conditions.
Store Noveltreat 2.4 mg pen in a refrigerator at 2°C-8°C before first use. Do not freeze or expose to heat or sunlight. After opening, keep it at room temperature for a limited period as advised. Always keep the pen capped and out of reach of children.